Phibro Animal Health (NASDAQ:PAHC) Downgraded by StockNews.com to Buy

StockNews.com downgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a strong-buy rating to a buy rating in a research note issued to investors on Sunday.

Several other analysts have also recently weighed in on the stock. Morgan Stanley upped their price objective on shares of Phibro Animal Health from $20.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 17th. Barclays increased their price target on Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $20.50.

Phibro Animal Health Stock Down 6.7 %

Shares of NASDAQ PAHC opened at $20.05 on Friday. Phibro Animal Health has a 52-week low of $10.03 and a 52-week high of $25.98. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.69 and a current ratio of 3.23. The business has a fifty day moving average of $22.75 and a two-hundred day moving average of $21.13. The stock has a market cap of $812.09 million, a PE ratio of 46.63, a PEG ratio of 0.58 and a beta of 0.53.

Phibro Animal Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 18th. Stockholders of record on Wednesday, November 27th were paid a dividend of $0.12 per share. The ex-dividend date of this dividend was Wednesday, November 27th. This represents a $0.48 annualized dividend and a dividend yield of 2.39%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 111.63%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Sofinnova Investments Inc. bought a new position in Phibro Animal Health in the second quarter valued at about $3,975,000. Geode Capital Management LLC grew its position in shares of Phibro Animal Health by 5.7% during the 3rd quarter. Geode Capital Management LLC now owns 507,469 shares of the company’s stock worth $11,430,000 after buying an additional 27,201 shares during the period. Barclays PLC grew its position in shares of Phibro Animal Health by 25.7% during the 3rd quarter. Barclays PLC now owns 143,337 shares of the company’s stock worth $3,228,000 after buying an additional 29,271 shares during the period. Algert Global LLC raised its stake in shares of Phibro Animal Health by 521.1% during the third quarter. Algert Global LLC now owns 71,335 shares of the company’s stock worth $1,606,000 after buying an additional 59,850 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Phibro Animal Health by 3.1% in the third quarter. BNP Paribas Financial Markets now owns 24,336 shares of the company’s stock valued at $548,000 after buying an additional 729 shares during the period. 99.34% of the stock is currently owned by institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.